Posted by Michael Wonder on 26 Aug 2021
CellMax Life earns FDA breakthrough device designation for colon cancer & pre-cancerous adenomas screening blood test
25 August 2021 - FirstSight now qualifies for expedited FDA review process as a blood test for detection of advanced neoplasia (colorectal cancer & pre-cancerous advanced adenomas).
CellMax Life announced today that its FirstSight pre-cancer and cancer detection blood test has received breakthrough device Designation from the U.S. FDA.
The blood test is based on CellMax Life's proprietary platform technology for detecting cancer and pre-cancer.
